Tenax Therapeutics (NASDAQ:TENX) Now Covered by Analysts at StockNews.com

StockNews.com began coverage on shares of Tenax Therapeutics (NASDAQ:TENX) in a research note issued to investors on Sunday. The firm issued a sell rating on the specialty pharmaceutical company’s stock.

Tenax Therapeutics Stock Performance

Shares of TENX stock opened at $3.01 on Friday. The business has a 50 day moving average of $3.45 and a two-hundred day moving average of $7.20. Tenax Therapeutics has a 52 week low of $2.77 and a 52 week high of $61.20.

Tenax Therapeutics (NASDAQ:TENX) last released its quarterly earnings results on Tuesday, May 14th. The specialty pharmaceutical company reported ($3.12) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.40) by ($0.72). On average, research analysts forecast that Tenax Therapeutics will post -7.96 EPS for the current year.

About Tenax Therapeutics

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.